| Popis: |
As the number of cancer patients increases and new (mostly expensive) treatment options are evolving rapidly, a critical evaluation of the value of new treatments is required in order to maintain access to new drugs and affordable cancer care. In the Netherlands, the Dutch Society of Medical Oncology- CieBOM (NVMO CieBOM) has an unique role in assessment of the value and use of new oncological drugs, next to the National Committee of Health Insurance (cieBAG) and the Dutch Health Care Institute. CieBOM developed transparent criteria for approval of oncological drugs in several settings, and recently also criteria for drugs only tested in non-randomised studies have been developed. |
